RegulationBreakthrough Therapy (United States), Fast Track (United States), Emergency Use Authorization (United States), Orphan Drug (United States), Special Review Project (China), Priority Review (United States)

Structure/Sequence

Molecular FormulaC16H17N7O2S

InChIKeyXUZMWHLSFXCVMG-UHFFFAOYSA-N

CAS Registry1187594-09-7

224

Clinical Trials associated with Baricitinib

NCT06381661

/ Not yet recruitingPhase 3IIT

PALETTE- Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Bayesian Basket Trial"

PALETTE is a perpetual adaptive platform to efficiently study sepsis interventions within 'treatable traits' in all-ages patients enabling prompt evaluation of pandemic treatments. Treatable traits, therapeutic targets identified by phenotypes or endotypes (defined by biological mechanism or by treatment response) through validated biomarkers (measurable characteristic reflecting normal or pathogenic processes, or treatment responses), may include multi-omics, cellular, immune, metabolic, endocrine features, or intelligent algorithms. PALETTE Bayesian adaptive design enables parallel investigations of multiple interventions for sepsis, and quick inclusion of pandemic pathogens. PALETTE's new conceptual model will respond to the challenges of standard approaches, i.e. series of sepsis trials, each investigating one or two interventions, expensive, time consuming, and inappropriate in pandemic context.

Start Date01 Apr 2026

Sponsor / Collaborator

Assistance Publique des Hôpitaux de Paris SA

NCT06923072

/ RecruitingPhase 2IIT

A Phase IIa Trial of Baricitinib in the Treatment of Kohlmeier-Degos Disease Patients With Neurological Involvement

Background:
Kohlmeier-Degos (KD) is a rare disease that causes inflammation and blood clots, leading to blockages in small blood vessels. These blockages can result in K-D lesions throughout the body, affecting the skin, lungs, heart, spinal cord, and brain. KD can be fatal. No treatment exists for this disease.
Objective:
To test a study drug (baricitinib) in people with brain and spine lesions caused by KD disease. Baricitinib is FDA approved to treat other disorders but has not yet been tried in people with KD.
Eligibility:
People aged 18 years or older with KD-related lesions in the brain and spine.
Design:
Participants will be screened; they will have a physical exam with blood tests. They will also have a baseline visit that may include multiple tests, such as imaging scans of the brain and spine; a lumbar puncture to collect fluid from the spinal canal; and a meeting with a neurologist. They will fill out a questionnaire about their health. They will continue to take their normal medications throughout the study.
Baricitinib is a tablet taken by mouth. Participants will remain on their normal medications for 12 weeks after their baseline visit. Then they will also take the study drug once a day at home for 24 weeks.
Participants will have clinic visits every few weeks for up to 40 weeks. Some visits may take 1 to 4 days. Baseline tests will be repeated 3 more times during study visits. Other visits will require only blood tests; these may be done by local labs that will send the samples to NIH; 2 visits may be done via telehealth....

Start Date02 Jun 2025

Sponsor / Collaborator

National Heart, Lung & Blood Institute

NCT06868381

/ Not yet recruitingPhase 2IIT

A Phase IIa, Single-Site, Open-Label Trial of Baricitinib in Patients With Cardiac Sarcoidosis

The goal of this clinical trial is to learn if baricitinib in combination with a background steroid-sparing medication can treat active cardiac sarcoidosis in adults. The main question it aims to answer is:
- In patients with active cardiac sarcoidosis, does treatment with baricitinib improve cardiac sarcoidosis disease activity as assessed by changes on cardiac FDG-PET/CT?
Participants will:
* Take baricitinib in combination with a steroid-sparing therapy for up to 16 weeks
* Visit the clinic every two to four weeks for checkups and tests
* Be asked to complete questionnaires to see how they feel on baricitinib and medication diaries to record when they take baricitinib

Start Date12 May 2025

Sponsor / Collaborator

Stanford University

[+1]

100 Clinical Results associated with Baricitinib

100 Translational Medicine associated with Baricitinib

100 Patents (Medical) associated with Baricitinib

3,617

Literatures (Medical) associated with Baricitinib

31 Dec 2025·JOURNAL OF DERMATOLOGICAL TREATMENT

Risk of serious infection with JAK inhibitors in immune-mediated inflammatory skin diseases: a meta-analysis of randomized clinical trials

Review

Author: Ji, Chao ; Lv, Xiaoqing ; Qin, Kun ; Mao, Jing ; Ou, Yushan ; Ruan, Shifan ; Su, Xinhong

BACKGROUND:

Emerging research suggests that Janus kinase-signal transducer and activator of transcription (JAK-STAT) inhibitors may be associated with a higher risk of serious infection for patients with rheumatoid arthritis. However, there is no consensus on whether JAK inhibitors increase the risk of serious infection in patients with Immune-mediated inflammatory skin diseases (IMISDs).

OBJECTIVES:

To ascertain the correlation between JAK inhibitor use and the risk of serious infection in patients with IMISDs.

METHODS:

PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), and registered Clinical Trials were searched up to June 1, 2024, using specific search terms related to JAK inhibitors and IMISDs. Randomized clinical trials (RCTs) comparing JAK inhibitors with a control group in patients with IMISDs were included. Studies focusing on cohort studies, case reports, case series, review articles, pooled analysis studies, post hoc analyses and topical JAK inhibitors were excluded. Data were extracted independently by two authors, focusing on serious infections defined according to each study's criteria. Crude numbers for serious infections were pooled and underwent meta-analysis. We assessed the primary outcome regarding the occurrence of severe infections for each study.

RESULTS:

Thirty-two randomized clinical trials involving 11,917 patients were included. Serious infections were reported in 0.62% of patients receiving JAK inhibitors and 0.51% of controls. Meta-analysis found no significant increase in risk of serious infection (I²=0.00%, RR, 0.68; 95% CI, 0.43-1.07). Subgroup analyses revealed no significant heterogeneity based on condition (p = .56) or medication (p = .69).

CONCLUSIONS:

This meta-analysis demonstrates that JAK inhibitors do not significantly increase the risk of serious infections in IMISD patients compared to control treatments. These findings support the safety of JAK inhibitors in this population. Future research should focus on real-world evidence to further assess their risk-benefit profile in dermatological practice.

01 Dec 2025·JOURNAL OF CLINICAL IMMUNOLOGY

Baricitinib-Induced Remission of Alopecia Universalis in a Child with NFKB2-Associated Immune Dysregulation

Letter

Author: Flinn, A M ; Browne, F ; Blokhuis, C ; Irvine, A D ; Leahy, T R

01 Dec 2025·Current Hematologic Malignancy Reports

Emerging Therapeutic Approaches for Anemia in Myelofibrosis

Review

Author: Harrington, Patrick ; Palumbo, Giuseppe A ; Chifotides, Helen T ; Duminuco, Andrea ; Bose, Prithviraj ; Torre, Elena ; Vetro, Calogero

PURPOSE OF REVIEW:

In this review, we highlight conventional agents and novel emerging therapeutic strategies to treat anemia in MF.

RECENT FINDINGS:

Anemia is a common and challenging feature of myelofibrosis (MF). The pathobiology of anemia is multifactorial, including progressive bone marrow fibrosis, decreased erythropoiesis due to high hepcidin levels leading to iron sequestration in the reticuloendothelial system, hypersplenism, erythropoiesis inhibition by myelosuppressive JAK inhibitors (ruxolitinib, fedratinib), and others. MF-associated anemia has a negative impact on survival. Conventional agents to manage anemia include erythropoiesis-stimulating agents, danazol, corticosteroids, and immunomodulatory agents, but responses are infrequent and lack durability. Notable advancements have emerged in developing novel treatments for anemia in MF, including the regulatory approval of momelotinib (ACVR1/JAK1/2 inhibitor) in 2023 and development of novel promising agents targeting hemojuvelin and activins. Momelotinib and pacritinib (ACVR1/JAK2 inhibitor) are the preferred JAK inhibitors for patients with cytopenias (anemia, thrombocytopenia). Luspatercept and elritercept are activin receptor ligand traps, promoting erythroid maturation and late-stage erythropoiesis. Currently, luspatercept is being evaluated in a phase 3 trial (INDEPENDENCE™) for anemia in MF patients who are on a JAK2 inhibitor and require transfusions, and in a phase 2 trial (ODYSSEY) in combination with momelotinib in MF patients who are transfusion dependent, whether or not on a JAK inhibitor. Interim results of the RESTORE trial demonstrated that elritercept significantly decreased transfusions in MF patients. DISC-0974 is a first-in-class anti-hemojuvelin (positive hepcidin regulator) monoclonal antibody that decreased hepcidin expression, increased serum iron, and enhanced erythropoiesis in anemic patients with MF in a phase 1b/2 study. Burgeoning studies of novel anemia-targeted agents and combinations are significantly improving the quality of life and outcomes of patients with MF. The recent approval of momelotinib to treat MF with anemia and the emerging novel anemia-directed strategies in early and advanced clinical development have ushered in a new era in the treatment of MF-related anemia.

687

News (Medical) associated with Baricitinib

26 May 2025

·pharma.economictimes.indiatimes.com

Trump's MFN pricing plan may hobble Sun Pharma's specialty ride in US, say analysts

New Delhi: What distinguishes India’s largest drug manufacturer, Sun Pharma , among its domestic peers might work against the company's future growth ambitions, on account of a new pricing model announced by the US President earlier this month. Speaking at a webinar hosted by ET Pharma over the new Most-Favoured Nation (MFN) pricing model, a market analyst voiced that while the Indian Pharma industry stands immune with generics, Sun Pharma, which has made specialty novel drugs as its key focus, might encounter some bumps on its future ambition track. “The proposed model is meant to play on the price differentiation of drugs and if it gets implemented it is going to be disruptive for the innovator pharma industry and cutting down prices by up to 50-60 per cent might push innovators into losses," said Vishal Mabchanda, a pharma analyst at Systematix Group. “Among the Indian companies, Sun Pharma that have an innovative portfolio, stands to get impacted," he added. According to an price differential analysis undertaken by the US department of Health and Human Services, using 2022 data, “US prices were closer to those in other countries—at 173 and 213 percent of international prices—when applying the overall and retail-dispensed, and for only brand-name drugs, US prices stands 308 per cent of prices in other countries.” However, at Sun Pharma's last earnings call for Q4 FY25, the company Chairman and MD, Dilip Shanghvi said that, “currently the order is at a voluntarily level and we have wait for greater clarity on this.” At the webinar, Nishith Sanghvi, Director, Corporates at India Ratings, also underlined that, the channels which procure drugs in US plays a major role in deciding the prices and notably, while announcing the order US President Donald Trump specifically voiced that the administration wants to remove the middle-men from the distribution chains. “The Secretary of Health and Human Services will establish a mechanism through which American patients can buy their drugs directly from manufacturers who sell to Americans at a “Most-Favored-Nation” price, bypassing middlemen,” the Factsheet on the order issued from the Whitehouse suggests. “When the order was announced, the market reaction reflected that the proposed order is highly unlikely to be implemented in its initial proposed format and it will likely be in a more diluted form,” Manchanda noted. Besides this, the chance of a legal challenge is always there on the horizon as seen in the past during Trump's first term-though the order was restricted to the government-funded Medicare program. Following the Ranbaxy fiasco, what is often described as Sun Pharma’s 'second stint' saw the Indian drugmaker shift its focus from the traditional generics ANDA pathway to novel innovations in specialty therapeutic segments. Over the last few years, driven by in-licensing agreements and in-house capabilities, the company has established a solid foundation in this segment. In the latest concluded quarter ended March this year, while the company reported a 19 per cent year-on-year (YoY) decline in its net profit , the global specialty sales went up by 8.6 per cent to $295 million (around ₹2,500 crore)--accounting for 19.9 per cent of the total quarterly sales. Moreover, for the full fiscal period, the specialty portfolio accounted for 19.7 per cent of the total global sales and generated $1,216 million (around ₹10,330 crore), up by 17.1 per cent against the previous fiscal. Expanding its specialty portfolio, the drugmaker is looking to launch two of its approved pipeline candidates--Leqselvi and Unloxcyt---in the near future. Leqselvi , a JAK 1/2 inhibitor was approved by the FDA in July 2024 for treatment of adults with severe alopecia areata (a type of hair loss). The company's plans were mired by a court ruling which blocked the drug launch in November 2024, but in April this year the US Court of Appeals for the Federal Circuit lifted the preliminary injunction and cleared its market entry. According to experts, “Sun Pharma’s Leqselvi higher dose of 8 mg twice daily, positions it in a stronger position as the higher dose will have a slightly better efficacy in comparison to Eli Lilly’s Olumiant which is taken at 2mg or 4mg per day for severe alopecia areata treatment.” A market assessment report published by GlobalData expects that, “total sales of Leqselvi is expected to reach $698.3 million (around ₹5,930 crore) in the US by 2033, accounting for approximately 35 per cent of the anticipated $2 billion (₹1,7000 crore) market for alopecia areata therapies in the country. Besides this, in March this year, the Indian drugmaker acquired a US-based immunotherapy and targeted oncology company, Checkpoint Therapeutics , with an upfront payment of up to $355 million (around ₹3000 crore). Unloxcyt (cosibelimab-ipdl) has received approval from the USFDA for the treatment of adults with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or curative radiation. Industry experts suggest that in the US, Onco-derma drugs have the highest profit margin among all therapeutic segments. Announcing, the company's Q4 FY25 results, Dilip Shanghvi said that, "The near-term pipeline in Global Specialty is promising, with products such as Leqselvi and Unloxcyt—the latter through our recently announced Checkpoint acquisition—offering significant improvements in patient care and we look forward to specialty drugs becoming an increasingly important part of our business." For FY25, the company's total revenue of ₹52,578 crore and the R&D spent (largely aligned for specialty projects) stands at ₹3,248 crore–accounting for nearly 6.2 per cent of total sales. While the administration is yet to convey the price targets, the recent developments reflect that with a majority in both houses and the commendation on the executive machinery, there is no holding back on the part of US. For the Indian drugmaker, identified with the unpredictable strategy of turning niche gaps into million-dollar bets, the road ahead may soon be shaped by equally unconventional policies and mounting unpredictability. By Abhijeet Singh ,

Drug ApprovalAcquisitionImmunotherapyLicense out/inBiosimilar

23 May 2025

·pharma.economictimes.indiatimes.com

Researchers identify best drugs for severe COVID

London: A class of drugs known as Janus kinase, or JAK, inhibitors, which work by slowing down the immune system, should be the first-line therapy for patients hospitalized for COVID-19, researchers reported in The Lancet Respiratory Medicine. The researchers analyzed individual outcomes of nearly 13,000 adults hospitalized for COVID who participated in 16 randomized trials comparing JAK inhibitors to other drugs or placebos between May 2020 and March 2022. Overall, 11.7 per cent of patients who received JAK inhibitors died by day 28, compared with 13.2 per cent of those who received other treatments such as the steroid dexamethasone or medications that block the signaling of the inflammatory protein IL-6. After accounting for individual risk factors, the odds of death by day 28 were 33 per cent lower in the JAK inhibitor group. "These results should inform World Health Organization COVID-19 treatment guidelines, both in the USA and Europe," an editorial published with the study said. "Although the pandemic has passed and COVID-19 is not nearly as rampant as it was previously, delays in disseminating and adopting best-evidence treatment practices can only be harmful." JAK inhibitors include Pfizer's Xeljanz (tofacitinib), Eli Lilly's Olumiant (baricitinib), and AbbVie's Rinvoq (upadacitinib). JAK inhibitors also decreased the need for new mechanical ventilation or other respiratory support, and allowed for faster discharge from hospital by about 1 day, with fewer serious adverse events. The findings were true regardless of patients' COVID vaccination status. "The certainty of the authors' conclusion that JAK inhibitory therapy for the treatment of patients admitted to hospital for COVID-19 provides a significant mortality benefit is further supported when the analysis is limited to placebo-controlled studies," the editorial says. FOR VERY LARGE FETUSES, EARLY INDUCTION MAY BE BENEFICIAL When a near-term fetus is expected to be larger than most other newborns at birth, it might be safer to induce labor a bit ahead of the due date, new data suggest. Births of large babies can be complicated by shoulder dystocia, an emergency situation in which their shoulders become impacted on the mother's pubic bones after their head has emerged, preventing the rest of the body from being delivered spontaneously. To see if inducing labor ahead of schedule would reduce the risk of shoulder dystocia, researchers recruited 2,893 women whose fetuses appeared on ultrasound to be larger than 90 per cent of other similarly-aged fetuses. They randomly assigned the women to receive standard care or induction between 38 weeks and 38-weeks-and-four-days of gestation. Induction was expected to result in an earlier birth and a lower birth weight than standard care. Overall, in the so-called Big Baby Trial, there was no difference between the groups in rates of shoulder dystocia, probably because many of the women in the standard care group delivered before 38 weeks, and so their babies were smaller than predicted. When the analysis was limited to women who did not deliver before 38 weeks, shoulder dystocia occurred in 2.3% of babies in the induction group versus 3.7 per cent of those in the standard care group. The induction group delivered on average about 8 days earlier, and their babies weighed about 8 ounces (213 grams) less, compared to the usual-care group. After accounting for individual risk factors, the odds of shoulder dystocia were 38% lower in the induction group versus usual care in women whose pregnancies lasted beyond 38 weeks. Induction of labor was also associated with a lower likelihood of cesarean delivery and fewer maternal complications, researchers reported in The Lancet. An editorial published with the report notes, "The Big Baby Trial joins an accumulating body of literature... indicating that induction of labor either does not alter or might reduce the risk for needing cesarean delivery" when a larger fetus is suspected. NEW BED NET TREATMENT TARGETS MALARIA PARASITES IN MOSQUITOES Bed nets may once again become useful against malaria in endemic regions, with use of a chemical that targets the malaria-causing parasite in mosquitoes rather than the mosquitoes themselves, researchers reported on Wednesday in Nature. The use of long-lasting insecticides in bed nets significantly reduced malaria cases and deaths between 2000 and 2015, but the method eventually became less effective due to the rise of insecticide resistance. The researchers from the Harvard T. H. Chan School of Public Health in Boston screened 81 endochin-like quinolones (ELQs), a class of experimental antimalarial agents, and identified two that block the development of the malaria parasite by targeting a key protein in the parasite. The ELQs were effective even against mosquitoes that were resistant to traditional insecticides. "Malaria control desperately needs innovation," study co-author Dr. Flaminia Catteruccia said in a statement. "Our chemistry collaborators at Oregon Health and Science University were able to generate these compounds inexpensively, which would allow this approach to be integrated into existing bed net infrastructure at a competitive cost," study leader Alexandra Probst said in a statement. (Reporting by Nancy Lapid; additional reporting by Shawana Alleyne-Morris; Editing by Bill Berkrot)

Clinical ResultClinical Study

21 May 2025

·www.einpresswire.com

Veterinary Dermatology Drugs Market to Reach $32.1 Billion by 2035, Rising from $17.6 Billion in 2024 at 8.8% CAGR

As pet insurance coverage increases and consumers demand higher standards of care, the veterinary dermatology drugs market is set to grow steadily. INDORE, INDIA, May 21, 2025 / EINPresswire.com / -- Veterinary dermatology drugs market was valued at $19.8 billion in 2024 and is anticipated to grow at a CAGR of 8.8% during the forecast period (2025-2035). Increasing pet ownership, a growing number of dermatology drugs clinical trials and approvals, an increasing rate of parasitic and other skin diseases in animals, and market players' investments are the primary drivers of the market growth. For instance, in September 2024, the FDA approved Zenrelia (ilunocitinib tablets), an oral immunosuppressant for the treatment of itching and atopic dermatitis in dogs aged one year and older. Zenrelia is accessible by prescription and has several tablet strengths. The emergence of new and targeted therapies, such as biologics and natural-based products, is further driving market growth. Veterinarians are now moving toward a more individualized treatment of skin conditions in animals, helping the trend toward more specialized and accurate treatment options. For instance, in August 2024, Boehringer Ingelheim India entered into a strategic distribution collaboration with Vvaan Lifesciences Pvt Ltd to strengthen its pet parasiticide portfolio and increase its foothold in the pet health space in India, worth approximately $124.51 million. With this partnership, the company focuses on enhancing quality pet healthcare in Tier 2 and smaller cities, utilizing the knowledge of Vvaan to offer better services in these areas as well as enhancing veterinary care levels throughout the country. Click To get a Sample PDF (Including Full TOC, Graphs & Charts, Table & Figures) @ https://www.omrglobal.com/request-sample/veterinary-dermatology-drugs-market Market Trends Rising Pet Acquisition and Spending on Pet Health to Propel Market Growth The surging trend towards the ownership of pets, especially among millennials and Gen Z, has been a dominant growth force within the market of veterinary dermatology drugs. Pets are considered family more and more, with all that follows their well-being that increases attention being devoted to skin, as part of overall pet wellness. That means more spending on veterinary health treatments, such as dermatological medications for problems of allergies, infection, and dermatitis. Pet owners are more conscious of the importance of curing skin disorders in pets, and this is increasing the demand for specific dermatology drugs. As there is an increasing growth in the pet care industry, both in developed and emerging economies, demand for safe, effective, and low-cost veterinary dermatology drugs is expected to rise, thereby driving market growth. For instance, in September 2024, Elanco launched Zenrelia (ilunocitinib tablets), an oral once-daily JAK inhibitor for the control of canine atopic and allergic dermatitis in dogs 12 months of age and older. Zenrelia offers excellent itch relief and value, making it a safer and more effective alternative to others. Advancements in Veterinary Dermatology Products to Fuel Market Growth Technological advancements and innovations in veterinary dermatology drugs are significant market drivers. Growing numbers of more specific and more efficient dermatology drugs for pets have improved the success rates for the treatment of numerous skin diseases, including atopic dermatitis, bacterial infestations, and parasitic infestations. All this has led to the use of new forms of drugs, biologics, and immunotherapy preparations that are more effective with fewer side effects compared to the traditional treatment. In addition, the increasing use of such drugs in animal clinics and better diagnostic equipment for dermatology conditions have contributed to improving their application. The progress of veterinary dermatology through innovative treatments, the demand for specialized drugs to treat complicated skin diseases in animals, will drive market growth. Order Your Report Now For A Swift Delivery: https://www.omrglobal.com/buy-now/veterinary-dermatology-drugs-market Regional Outlook North America Holds a Major Market Share North America holds a majority of market share, this is primarily due to the rising number of pets in developed nations such as the US and Canada and the accessibility of leading veterinary dermatology companies in the region. Increased pet healthcare spending, better-equipped veterinary infrastructure, and greater awareness regarding animal dermatological disorders are further contributing to increased demand for veterinary dermatology products in the region. The rising number of veterinary professionals in North America helps drive market growth. According to the Workforce Needs in Veterinary Medicine report prepared by the National Academy of Sciences states that the active veterinarians in the region were ~90,200 in 2012; this is expected to grow to 108,900 by 2030. The growth in veterinary clinics is projected to increase access to high-end diagnostic and therapeutic solutions, fueling the demand for veterinary dermatology products in North America. Additionally, developments in veterinary dermatological therapies, including monoclonal antibody therapies (such as Cytopoint) and new topical therapies, are driving the market. Asia-Pacific is the fastest-growing region of Veterinary Dermatology Drugs Asia-Pacific is anticipated to register the fastest CAGR during the forecast period. Due to rising growth in economies of the Asia-Pacific region, there is an apparent increase in the number of middle-class populations, increased disposable incomes, and growing urbanization. Market Players have started to grasp opportunities in such developing markets. China, specifically, enjoys high momentum on the back of advancements in veterinary drugs and government backing for pet care. For instance, in October 2024, China's Ministry of Agriculture and Rural Affairs approved FelicaMed Biotechnology's Lirucitinib, a Class I animal drug for the treatment of canine pruritus. Licensed to a Chinese subsidiary, Elanco, Lirucitinib is a JAK inhibitor that disrupts the itch-scratch-inflammation cycle, offering instant relief. This collaboration is a landmark in China's veterinary innovation and reaffirms FelicaMed's focus on improving pet health solutions. Moreover, partnerships among local firms and international leaders (such as FelicaMed and Elanco in China) are fueling the launch of innovative medicines tailored to regional market requirements. Market Segmentation and Growth Areas Companion Animal is expected to become the Largest Segment Growth in pet adoption has thus promoted a greater demand for quality pet products and services. This increase has been contributed to by improved knowledge of the pet requirements as a result of advances in veterinary medicine, along with information spreading on the subject. Owners are providing high preference for high-class pet foods, toys, and other health items for animals. Topical segment to occupy a Considerable Market Share Topical drugs have high specificity and may easily be applied directly at the site of disease without being injected into blood streams, hence reducing overall body reactions or changes from other drug components. Topical drugs are favored by veterinarians because they are easier to deliver than oral suspensions and tablets. They offer quicker relief when applied to the diseased spot and may be employed in the treatment of many skin ailments. While the need for quality therapy options by consumers continues to increase, the topical category is at the forefront in regards to animal health care solutions innovation targeted at efficacy, safety, and ease of use. Market Limitations and Challenges • Lack of Awareness among Pet Owners: Pet owners usually don't recognize dermatological signs or symptoms for veterinary intervention. Such ignorance can lead to undertreatment and underdiagnosis of animal skin disease. • Shortage of Dermatology-Veterinary Trained Specialists: There is a global shortage of veterinarians with dermatology training, contributing to inaccurate diagnosis and treatment. This leaves a gap in sophisticated dermatological treatment, particularly in rural and underprivileged communities. Market Players Outlook Some of the key players in the global veterinary dermatology drugs market are Bimeda, Inc., Ceva Sante Animale, Elanco, Merck & Co., Inc., and Zoetis Inc., among others. The players are emphasizing more business growth and product development by implementing strategies such as collaborations, mergers, and acquisitions to be competitive in the market. For instance, in November 2024, Bimeda, Inc. (Ireland) extended its anti-parasitic portfolio with the introduction of MoxiSolv Injection (moxidectin), the FDA-approved injectable, marketed in a non-shattering 500 mL plastic bottle. Request for Customization: https://www.omrglobal.com/report-customization/veterinary-dermatology-drugs-market Recent Developments • In November 2024, Merck & Co., Inc. (US) secured a European Commission grant for marketing authorization of BRAVECTO TriUNO, a new formulation of fluralaner in dogs for treating internal and external parasites, approved in Peru, Guatemala, Nicaragua, and Costa Rica. • In September 2024, Norbrook (Ireland) invested $1.5 million to formally launch the newly upgraded sterile injectable manufacturing site in Newry, Northern Ireland, to manufacture products that are vital in treating and preventing infection in livestock and pets. • In July 2024, Invetx (US) was acquired by Dechra Pharmaceuticals plc (UK) that is a company focusing on creating protein-based therapeutics for companion animals' chronic diseases using monoclonal antibodies (mAbs). Some of the Key Companies in the Veterinary Dermatology Drugs Market Include- • AB Science • Bayer AG • Bimeda Holdings Ltd. • Bioiberica S.A.U. • Boehringer Ingelheim International GmbH • Ceva Santé Animale • Elanco Animal Health Inc. • IDEXX Laboratories Inc. • Indian Immunologicals Ltd. • Leti Pharma, S.L.U. • Mars, Inc. • Merck & Co., Inc. • Novartis AG • SAVAVET • Toray Industries, Inc. • Vetoquinol Group • Virbac Corp. • Vivaldis Health & Foods Pvt. Ltd. • Zoetis Inc. Market Segmentation Analysis Global Veterinary Dermatology Drugs Market by Type • Antifungal Drugs • Antibacterial Drugs • Antiparasitic Drugs Global Veterinary Dermatology Drugs Market by Animal Type • Companion Animals • Livestock Animals Global Veterinary Dermatology Drugs Market by Route of Administration • Topical • Oral • Injectable Global Veterinary Dermatology Drugs Market by Distribution Channel • Hospital Pharmacies • Retail • E-commerce Global Veterinary Dermatology Drugs Market by Indication • Parasitic Infections • Allergic Infections • Others (Skin Cancer) Regional Analysis • North America o United States o Canada • Europe o UK o Germany o Italy o Spain o France o Rest of Europe • Asia-Pacific o China o India o Japan o South Korea o ASEAN Economies (Singapore, Thailand, Vietnam, Indonesia, and Other) o Australia and New Zealand o Rest of Asia-Pacific • Rest of the World o Latin America o Middle East and Africa Inquiry Before Buying: https://www.omrglobal.com/inquiry-before-buying/veterinary-dermatology-drugs-market Anurag Tiwari Orion Market Research Pvt Ltd + +91 91798 28694 email us here Visit us on social media: LinkedIn Facebook X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Drug ApprovalAcquisition

100 Deals associated with Baricitinib

External Link

KEGG	Wiki	ATC	Drug Bank
D10308	Baricitinib	L04AA37	DB11817

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Enthesitis-Related Arthritis	European Union	Eli Lilly Nederland BV	21 Sep 2023
Enthesitis-Related Arthritis	Iceland	Eli Lilly Nederland BV	21 Sep 2023
Enthesitis-Related Arthritis	Liechtenstein	Eli Lilly Nederland BV	21 Sep 2023
Enthesitis-Related Arthritis	Norway	Eli Lilly Nederland BV	21 Sep 2023
Juvenile Idiopathic Arthritis	European Union	Eli Lilly Nederland BV	21 Sep 2023
Juvenile Idiopathic Arthritis	Iceland	Eli Lilly Nederland BV	21 Sep 2023
Juvenile Idiopathic Arthritis	Liechtenstein	Eli Lilly Nederland BV	21 Sep 2023
Juvenile Idiopathic Arthritis	Norway	Eli Lilly Nederland BV	21 Sep 2023
Oligoarticular Arthritis	European Union	Eli Lilly Nederland BV	21 Sep 2023
Oligoarticular Arthritis	Iceland	Eli Lilly Nederland BV	21 Sep 2023
Oligoarticular Arthritis	Liechtenstein	Eli Lilly Nederland BV	21 Sep 2023
Oligoarticular Arthritis	Norway	Eli Lilly Nederland BV	21 Sep 2023
Polyarticular Juvenile Idiopathic Arthritis	European Union	Eli Lilly Nederland BV	21 Sep 2023
Polyarticular Juvenile Idiopathic Arthritis	Iceland	Eli Lilly Nederland BV	21 Sep 2023
Polyarticular Juvenile Idiopathic Arthritis	Liechtenstein	Eli Lilly Nederland BV	21 Sep 2023
Polyarticular Juvenile Idiopathic Arthritis	Norway	Eli Lilly Nederland BV	21 Sep 2023
COVID-19	Switzerland	Eli Lilly & Co.	19 Jun 2017
Alopecia Areata	European Union	Eli Lilly Nederland BV	13 Feb 2017
Alopecia Areata	Iceland	Eli Lilly Nederland BV	13 Feb 2017
Alopecia Areata	Liechtenstein	Eli Lilly Nederland BV	13 Feb 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Aicardi-Goutieres Syndrome	Phase 3	Japan	Eli Lilly & Co.	27 Oct 2020
Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature	Phase 3	Japan	Eli Lilly & Co.	27 Oct 2020
Melorheostosis	Phase 3	Japan	Eli Lilly & Co.	27 Oct 2020
Nakajo Syndrome	Phase 3	Japan	Eli Lilly & Co.	27 Oct 2020
STING-associated Vasculopathy With Onset in Infancy	Phase 3	Japan	Eli Lilly & Co.	27 Oct 2020
Systemic onset juvenile chronic arthritis	Phase 3	Japan	Eli Lilly & Co.	12 Feb 2020
Systemic onset juvenile chronic arthritis	Phase 3	Argentina	Eli Lilly & Co.	12 Feb 2020
Systemic onset juvenile chronic arthritis	Phase 3	Austria	Eli Lilly & Co.	12 Feb 2020
Systemic onset juvenile chronic arthritis	Phase 3	Belgium	Eli Lilly & Co.	12 Feb 2020
Systemic onset juvenile chronic arthritis	Phase 3	Brazil	Eli Lilly & Co.	12 Feb 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


SLE-BRAVE-I and SLE-BRAVE-II (Pubmed \| PLoS One)	Phase 3	Systemic Lupus Erythematosus	1,535	Baricitinib 4 mg	vazxksgnpw(xmqecbhpfk) = bympwvirzo eyyuswlaoi (rnkxkfzkuu )	Negative	30 Apr 2025
				Baricitinib 2 mg	vazxksgnpw(xmqecbhpfk) = bszasfuljz eyyuswlaoi (rnkxkfzkuu )
BRAVE-AA1 and BRAVE-AA2 (Pubmed \| Am J Clin Dermatol)	Phase 3	Alopecia Areata	1,303	Baricitinib 2 mg	wwunjhgfnd(ctqigfhsli) = jtswucelwb lbsvzuccnc (npuztkekhr ) View more	Positive	11 Apr 2025
				Baricitinib 4 mg	wwunjhgfnd(ctqigfhsli) = fnrsdivpvt lbsvzuccnc (npuztkekhr ) View more
BRAVE-AA1; BRAVE-AA2 (Pubmed \| Br J Dermatol)	Not Applicable	Alopecia Areata	-	Baricitinib 2 mg	yfozsdzfxj(zvadfnripw) = wbxqncuwuh kckpkzpdgb (lmyzkiaxwm )	Positive	03 Apr 2025
				Baricitinib 4 mg	yfozsdzfxj(zvadfnripw) = qdifclenjk kckpkzpdgb (lmyzkiaxwm )
NCT05723198 (BRAVE-AA-PEDS, Company_Website) Manual	Phase 3	Alopecia Areata	257	Baricitinib 4 mg	jpfqbgyaeb(gutpcyhwgc) = meetvgpdnx fepkztegud (eaglgatpyp ) View more	Positive	08 Mar 2025
				Baricitinib 2 mg	jpfqbgyaeb(gutpcyhwgc) = gtrarvaaoz fepkztegud (eaglgatpyp ) View more
NCT05188521 (Pubmed \| J Clin Invest)	Phase 2	Lichen Planus IFN-γ \| CD8+ \| CXCL13+	-	Baricitinib 2 mg	vxelkiqxvu(inlyzapdip) = dgbhlgqmvz vpfkadnley (dpndhnicnw )	Positive	16 Jan 2025
NCT03952559 (BREEZE-AD-PEDS, Pubmed \| J Dermatolog Treat)	Phase 3	Moderate Atopic Dermatitis \| Severe Atopic Dermatitis	467	Baricitinib 4-mg equivalent	wudxglvhpp(zpfcuojeam) = axtudduxkw wgqjsxpnfo (mrizxsbmms )	Positive	31 Dec 2024
NCT01885078 (RA-BEYOND, Pubmed \| Rheumatology (Oxford)) Manual	Phase 3	Rheumatoid Arthritis	-	Baricitinib 4 mg	ynymrgfumq(kdcxlstfph) = ogbiivdhhj mzuhwqzlyq (kqhfhkmlnt ) View more	Positive	01 Oct 2024
				Baricitinib 2 mg	ynymrgfumq(kdcxlstfph) = zsalujkjof mzuhwqzlyq (kqhfhkmlnt ) View more
NCT04088409 (CTgov)	Phase 3	Uveitis, Anterior \| Uveitis \| Juvenile Idiopathic Arthritis	30	Baricitinib (Baricitinib)	yhjacqkgze = rxqbjzmgyd yuivcpcvjw (kitbiujmft, mfrkldyqhf - cpfixbvgbf) View more	-	13 Aug 2024
				Adalimumab (Adalimumab)	hfheafuyyp(iyovflyfam) = wvmhepvoqa nutveclnhq (kgpxtciwai, tujcpabnph - funhbbifug) View more
NCT03570749 \| NCT03899259 (BRAVE-AA1; BRAVE-AA2, Pubmed)	Phase 3	Alopecia Areata	131	Baricitinib 4 mg	inexkirxhh(vniizuboqk) = progressive improvements dugkgrxivq (wfdpdpplca ) View more	Positive	21 Jun 2024
				Baricitinib 2 mg
EULAR2024 Manual	Not Applicable	Lung Diseases, Interstitial	60	Baricitinib	wywzeuznar(lvdcvxrqcd) = mpiqlwuxcl xcyorzfshu (shxrqvmnnb ) View more	Positive	05 Jun 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis